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Percutaneous transluminal coronary angioplasty (PTCA) was introduced in the late 
1970s as an alternative to coronary artery bypass graft surgery for coronary revascu-
larization; since then, it has been accepted as a safe, reliable, and effective treatment 
for coronary artery disease, and its use has spread worldwide. The introduction of 
first-generation drug-eluting stents (DES) transformed the practice of percutaneous 
coronary intervention (PCI) by drastically reducing the rate of in-stent restenosis. The 
efficacy of DES has largely been demonstrated in large randomized trials, leading to 
their current widespread use in clinical practice.
First- and second-generation DES have three major components, the stent platform, 
the antiproliferative drug, and the polymer. The stent platform is the scaffold of the 
stent. It provides the radial force to prevent vessel occlusion provoked by vessel injury 
following PCI. First-generation DES used stainless steel platforms. Cobalt-chromium 
and later platinum-chromium platforms used in second-generation DES permitted 
similar stents’ radial strength, while enabling a thinner strut design and subsequently 
significantly improved deliverability. Recently, bioabsorbable platforms that biode-
grade over a period of months have been developed, with the purpose of allowing the 
restoration of a normal vascular physiology and function over time. Ultimately, no 
foreign material is left exposed in the bloodstream. These stents may also potentially 
preserve reactive vasomotion and permit expansive remodeling.
There are several antiproliferative drugs with different modes of action. The goal 
of these drugs is to inhibit vascular smooth cell proliferation and migration, without 
affecting endothelial regeneration, and have anti-inflammatory/anti-thrombotic 
properties. Inhibitors of the mammalian target of rapamycin (mTOR) are the domi-
nant class of antiproliferative drugs used for DES. The first mTOR inhibitor used in 
clinical practice was sirolimus. First generation DES also used paclitaxel, which is a 
taxan drug, which acts as a cytotoxic drug through the stabilization of microtubules. 
Later derivatives include zotarolimus and everolimus (mTOR) and tacrolimus, which 
acts as a calcineurin inhibitor, and is a cytostatic agent with both antiproliferative and 
anti-inflammatory activities However, all these antiproliferative agents have shown 
detrimental local effects on the vascular wall and on endothelial function recovery 
after stenting. New drugs (biolimus, novolimus, and myolimus) have been developed 
and have shown promising results.
Stent polymers control elution of the antiproliferative drug over a variable period 
of time. Once drug elution has been completed, most polymers exert limited func-
tions and act as a potential trigger for local inflammation and hypersensitivity. The 
biocompatibility, composition, formulation, degradation delay of the polymer, phar-
macokinetics of the antiproliferative agent released by the polymer, and the manage-
ment of variation in polymer degradation delay have become new difficult challenges 
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DAPT = dual antiplatelet therapy
DES = drug-eluting stent(s)
mTOR = mammalian target of rapamycin
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for the development of stent polymers. An optimal polymer 
should mimic the endothelial lining in order to prevent late 
thrombotic complications, thus improving stent safety. Third-
generation DES use polylactic acids (poly-L-lactic acid and 
poly D,L-lactide-co-glycolide) as bioabsorbable polymers. 
Finally, another field of research is the development of stents 
that elute antiproliferative drugs without the need for poly-
mers. Preclinical studies support their use, but robust data 
are still lacking.
Current guidelines support the use of dual antiplatelet 
therapy (DAPT) for 6–12 months after DES implantation. In 
2006, the potential risk of late/very late stent thrombosis after 
DES implantation raised the question of prolonging DAPT 
even beyond the first year. However, prolonged DAPT has 
also clearly been associated with an increased risk of bleed-
ing. Availability of new biodegradable polymers and/or stents 
may shorten the duration of necessary DAPT and therefore 
minimize the risk of major bleeding to which it is associated.
